Adstiladrin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of bcg therapy, advances in gene delivery systems, rising bladder cancer incidence, clinical success of interferon therapies, regulatory support for gene therapy.

The growth in the forecast period can be attributed to expansion of gene therapy pipelines, increasing oncology precision medicine adoption, higher investment in viral vector manufacturing, improved long term efficacy data, growing awareness of nmibc treatment options. Major trends in the forecast period include rising adoption of gene therapy in oncology, focus on bladder cancer immunotherapy, growing use of viral vector technologies, shift toward localized cancer treatments, increasing demand for bcg unresponsive therapies.

The increasing incidence of bladder cancer is expected to drive the growth of the adstiladrin market in the coming years. Bladder cancer is a form of cancer that originates in the cells of the bladder, a hollow organ in the lower abdomen responsible for storing urine. The rise in bladder cancer cases is attributed to factors such as smoking, an aging population, exposure to environmental toxins, chronic bladder conditions, and improved diagnostic techniques. Adstiladrin plays an important role in bladder cancer treatment as it provides an effective option for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who do not respond to BCG therapy, thereby reducing the need for radical surgical interventions. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of urinary bladder cancer cases increased to 83,190 compared with 82,290 cases in 2023, representing a growth of 1.09%. Therefore, the rising incidence of bladder cancer is contributing to the growth of the adstiladrin market.

Rising healthcare expenditure is expected to propel the growth of the adstiladrin market going forward. Healthcare expenditure refers to the total spending by individuals, governments, and organizations on healthcare services, products, and infrastructure, including preventive, curative, rehabilitative, and palliative care. The increase in healthcare expenditure is driven by factors such as aging populations, a higher prevalence of chronic diseases, advancements in medical technology, growing demand for healthcare services, and increasing drug and treatment costs. Higher healthcare spending allows for greater investment in advanced therapies such as Adstiladrin, enhancing access to innovative treatment options for patients with high-risk bladder cancer. For example, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared with growth of 0.9% in 2022. UK healthcare expenditure amounted to approximately $317.63 billion (£292 billion) in 2023. Therefore, rising healthcare expenditure is driving the growth of the adstiladrin market.

Major companies operating in the adstiladrin market are focusing on the development of innovative products, such as adenovirus vector-based gene therapies, to enhance treatment outcomes. Adenovirus vector-based gene therapy involves the use of modified adenoviruses as delivery systems to transport therapeutic genes into target cells, enabling the treatment of genetic disorders and other diseases. For instance, in 2024, Ferring Pharmaceuticals, a Switzerland-based provider of urology and oncology therapies, announced the commercial launch of ADSTILADRIN (nadofaragene firadenovec-vncg). Key features of this therapy include intravesical administration via a catheter directly into the bladder every three months, a gene construct encoding interferon-alpha 2b that converts bladder wall cells into “interferon microfactories,” a favorable safety profile characterized mainly by low-grade adverse events, and demonstrated durable complete responses in patients with BCG-unresponsive NMIBC.

Major companies operating in the adstiladrin market are Ferring Pharmaceuticals Inc.

North America was the largest region in the adstiladrin market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the adstiladrin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adstiladrin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the adstiladrin market by increasing costs for imported viral vectors, specialized bioprocessing equipment, and cold-chain distribution services. These effects are most notable in regions dependent on advanced gene therapy imports, including asia pacific and emerging markets. Hospital and specialty clinic segments face higher procurement costs for novel gene therapies. On the positive side, tariffs are driving domestic investments in gene therapy manufacturing infrastructure. This supports localized production and strengthens long-term treatment accessibility.

The adstiladrin market research report is one of a series of new reports that provides adstiladrin market statistics, including adstiladrin industry global market size, regional shares, competitors with a adstiladrin market share, detailed adstiladrin market segments, market trends and opportunities, and any further data you may need to thrive in the adstiladrin industry. This adstiladrin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adstiladrin is a gene therapy treatment developed for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guérin (BCG) therapy. It contains nadofaragene firadenovec, a non-replicating adenoviral vector engineered to deliver the interferon alfa-2b gene directly into bladder cells. This mechanism induces localized production of interferon alfa-2b, a protein with antitumor activity, thereby strengthening the immune system’s ability to target and eliminate cancer cells.

The primary indications for Adstiladrin include high-risk non-muscle-invasive bladder cancer (NMIBC) and other forms of bladder cancer. High-risk NMIBC refers to bladder cancer in which the tumor remains limited to the inner lining of the bladder but carries a high risk of recurrence or disease progression. The therapy is distributed through multiple channels, including hospitals and clinics, retail pharmacies, and specialty pharmacies, and is used in both adult and geriatric patient populations.

The adstiladrin market consists of sales of gene therapy medications, adenoviral vectors, immune checkpoint inhibitors and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.